KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2016 - 2026)

Pacific Biosciences Of California has reported Other Accumulated Expenses over the past 15 years, most recently at $2.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 37.0% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 37.0%, while the annual FY2025 figure was $2.0 million, 37.0% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $2.0 million at Pacific Biosciences Of California, up from $1.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $8.3 million in Q4 2023 and troughed at $783000.0 in Q3 2024.
  • A 5-year average of $4.3 million and a median of $4.6 million in 2022 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 115.55% in 2021 and later tumbled 84.85% in 2024.
  • Year by year, Other Accumulated Expenses stood at $5.8 million in 2021, then rose by 25.59% to $7.2 million in 2022, then rose by 15.11% to $8.3 million in 2023, then crashed by 61.28% to $3.2 million in 2024, then tumbled by 37.0% to $2.0 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for PACB at $2.0 million in Q4 2025, $1.0 million in Q3 2025, and $2.6 million in Q2 2025.